Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

GLOFIL-125

&times

Overview

What is GLOFIL-125?



What does GLOFIL-125 look like?



What are the available doses of GLOFIL-125?

Sorry No records found.

What should I talk to my health care provider before I take GLOFIL-125?

Sorry No records found

How should I use GLOFIL-125?

GLOFIL-125 (Sodium Iothalamate I-125 Injection) is indicated for evaluation of glomerular filtration in the diagnosis or monitoring of patients with renal disease.

The suggested dose range employed in the average patient (70 kg) is as follows:    Continuous intravenous infusion: 20 to 100 μCi (0.74-3.7 megabecquerels) (Sigman, et al () method).    Single intravenous injection: 10 to 30 μCi (0.37-1.11 megabecquerels) (Cohen, et al () method).    The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.


What interacts with GLOFIL-125?

GLOFIL-125 should not be administered via a central venous line.



What are the warnings of GLOFIL-125?

Avoid spraying in eyes.


What are the precautions of GLOFIL-125?

General

As in the use of any radioactive material, care should be taken to minimize radiation exposure to the patient, consistent with proper patient management, and to insure minimum radiation exposure to occupational workers.

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides.

Rapid or bolus-like injections should be avoided.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate carcinogenic potential, mutagenic potential, or whether this drug affects fertility in males or females.

Pregnancy Category C

Animal reproduction studies have not been conducted with GLOFIL-125. It is also not known whether GLOFIL-125 can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. GLOFIL-125 should be given to a pregnant woman only if clearly needed.

Nursing Mothers

Radioiodine is excreted in human milk during lactation. It is not known whether GLOFIL-125 is excreted in human milk. Therefore, formula feedings should be substituted for breast feedings.

Pediatric Use

Safety and effectiveness in children have not been established.


What are the side effects of GLOFIL-125?

None reported.


What should I look out for while using GLOFIL-125?

GLOFIL-125 should not be administered via a central venous line.

None known.


What might happen if I take too much GLOFIL-125?

Sorry No Records found


How should I store and handle GLOFIL-125?

Refrigerate the product upon receipt at 2°C to 8°C.Diltiazem Hydrochloride Extended Release Tablets are supplied as:120 mg: white to off-white round tablets imprinted with “WPI” over “3360” in black ink, supplied in bottles of 30, 90 and 1000.180 mg: white to off-white round tablets imprinted with “WPI” over “3361” in black ink, supplied in bottles of 30, 90 and 1000.240 mg: white to off-white round tablets imprinted with “WPI” over “3362” in black ink, supplied in bottles of 30, 90 and 1000.300 mg: white to off-white round tablets imprinted with “WPI” over “3368” in black ink, supplied in bottles of 30, 90 and 1000.360 mg: white to off-white round tablets imprinted with “WPI” over “3363” in black ink, supplied in bottles of 30, 90 and 1000.420 mg: white to off-white round tablets imprinted with “WPI” over “3364” in black ink, supplied in bottles of 30, 90 and 1000.StoreAvoid excessive humidity and temperatures above 30°C (86°F).Dispense in tight, light resistant container as defined in USP.Rx Only.Watson Laboratories Inc.Corona, CA 92880 USARev. October 2005Diltiazem Hydrochloride Extended Release Tablets are supplied as:120 mg: white to off-white round tablets imprinted with “WPI” over “3360” in black ink, supplied in bottles of 30, 90 and 1000.180 mg: white to off-white round tablets imprinted with “WPI” over “3361” in black ink, supplied in bottles of 30, 90 and 1000.240 mg: white to off-white round tablets imprinted with “WPI” over “3362” in black ink, supplied in bottles of 30, 90 and 1000.300 mg: white to off-white round tablets imprinted with “WPI” over “3368” in black ink, supplied in bottles of 30, 90 and 1000.360 mg: white to off-white round tablets imprinted with “WPI” over “3363” in black ink, supplied in bottles of 30, 90 and 1000.420 mg: white to off-white round tablets imprinted with “WPI” over “3364” in black ink, supplied in bottles of 30, 90 and 1000.StoreAvoid excessive humidity and temperatures above 30°C (86°F).Dispense in tight, light resistant container as defined in USP.Rx Only.Watson Laboratories Inc.Corona, CA 92880 USARev. October 2005Diltiazem Hydrochloride Extended Release Tablets are supplied as:120 mg: white to off-white round tablets imprinted with “WPI” over “3360” in black ink, supplied in bottles of 30, 90 and 1000.180 mg: white to off-white round tablets imprinted with “WPI” over “3361” in black ink, supplied in bottles of 30, 90 and 1000.240 mg: white to off-white round tablets imprinted with “WPI” over “3362” in black ink, supplied in bottles of 30, 90 and 1000.300 mg: white to off-white round tablets imprinted with “WPI” over “3368” in black ink, supplied in bottles of 30, 90 and 1000.360 mg: white to off-white round tablets imprinted with “WPI” over “3363” in black ink, supplied in bottles of 30, 90 and 1000.420 mg: white to off-white round tablets imprinted with “WPI” over “3364” in black ink, supplied in bottles of 30, 90 and 1000.StoreAvoid excessive humidity and temperatures above 30°C (86°F).Dispense in tight, light resistant container as defined in USP.Rx Only.Watson Laboratories Inc.Corona, CA 92880 USARev. October 2005Diltiazem Hydrochloride Extended Release Tablets are supplied as:120 mg: white to off-white round tablets imprinted with “WPI” over “3360” in black ink, supplied in bottles of 30, 90 and 1000.180 mg: white to off-white round tablets imprinted with “WPI” over “3361” in black ink, supplied in bottles of 30, 90 and 1000.240 mg: white to off-white round tablets imprinted with “WPI” over “3362” in black ink, supplied in bottles of 30, 90 and 1000.300 mg: white to off-white round tablets imprinted with “WPI” over “3368” in black ink, supplied in bottles of 30, 90 and 1000.360 mg: white to off-white round tablets imprinted with “WPI” over “3363” in black ink, supplied in bottles of 30, 90 and 1000.420 mg: white to off-white round tablets imprinted with “WPI” over “3364” in black ink, supplied in bottles of 30, 90 and 1000.StoreAvoid excessive humidity and temperatures above 30°C (86°F).Dispense in tight, light resistant container as defined in USP.Rx Only.Watson Laboratories Inc.Corona, CA 92880 USARev. October 2005Diltiazem Hydrochloride Extended Release Tablets are supplied as:120 mg: white to off-white round tablets imprinted with “WPI” over “3360” in black ink, supplied in bottles of 30, 90 and 1000.180 mg: white to off-white round tablets imprinted with “WPI” over “3361” in black ink, supplied in bottles of 30, 90 and 1000.240 mg: white to off-white round tablets imprinted with “WPI” over “3362” in black ink, supplied in bottles of 30, 90 and 1000.300 mg: white to off-white round tablets imprinted with “WPI” over “3368” in black ink, supplied in bottles of 30, 90 and 1000.360 mg: white to off-white round tablets imprinted with “WPI” over “3363” in black ink, supplied in bottles of 30, 90 and 1000.420 mg: white to off-white round tablets imprinted with “WPI” over “3364” in black ink, supplied in bottles of 30, 90 and 1000.StoreAvoid excessive humidity and temperatures above 30°C (86°F).Dispense in tight, light resistant container as defined in USP.Rx Only.Watson Laboratories Inc.Corona, CA 92880 USARev. October 2005Diltiazem Hydrochloride Extended Release Tablets are supplied as:120 mg: white to off-white round tablets imprinted with “WPI” over “3360” in black ink, supplied in bottles of 30, 90 and 1000.180 mg: white to off-white round tablets imprinted with “WPI” over “3361” in black ink, supplied in bottles of 30, 90 and 1000.240 mg: white to off-white round tablets imprinted with “WPI” over “3362” in black ink, supplied in bottles of 30, 90 and 1000.300 mg: white to off-white round tablets imprinted with “WPI” over “3368” in black ink, supplied in bottles of 30, 90 and 1000.360 mg: white to off-white round tablets imprinted with “WPI” over “3363” in black ink, supplied in bottles of 30, 90 and 1000.420 mg: white to off-white round tablets imprinted with “WPI” over “3364” in black ink, supplied in bottles of 30, 90 and 1000.StoreAvoid excessive humidity and temperatures above 30°C (86°F).Dispense in tight, light resistant container as defined in USP.Rx Only.Watson Laboratories Inc.Corona, CA 92880 USARev. October 2005Diltiazem Hydrochloride Extended Release Tablets are supplied as:120 mg: white to off-white round tablets imprinted with “WPI” over “3360” in black ink, supplied in bottles of 30, 90 and 1000.180 mg: white to off-white round tablets imprinted with “WPI” over “3361” in black ink, supplied in bottles of 30, 90 and 1000.240 mg: white to off-white round tablets imprinted with “WPI” over “3362” in black ink, supplied in bottles of 30, 90 and 1000.300 mg: white to off-white round tablets imprinted with “WPI” over “3368” in black ink, supplied in bottles of 30, 90 and 1000.360 mg: white to off-white round tablets imprinted with “WPI” over “3363” in black ink, supplied in bottles of 30, 90 and 1000.420 mg: white to off-white round tablets imprinted with “WPI” over “3364” in black ink, supplied in bottles of 30, 90 and 1000.StoreAvoid excessive humidity and temperatures above 30°C (86°F).Dispense in tight, light resistant container as defined in USP.Rx Only.Watson Laboratories Inc.Corona, CA 92880 USARev. October 2005Diltiazem Hydrochloride Extended Release Tablets are supplied as:120 mg: white to off-white round tablets imprinted with “WPI” over “3360” in black ink, supplied in bottles of 30, 90 and 1000.180 mg: white to off-white round tablets imprinted with “WPI” over “3361” in black ink, supplied in bottles of 30, 90 and 1000.240 mg: white to off-white round tablets imprinted with “WPI” over “3362” in black ink, supplied in bottles of 30, 90 and 1000.300 mg: white to off-white round tablets imprinted with “WPI” over “3368” in black ink, supplied in bottles of 30, 90 and 1000.360 mg: white to off-white round tablets imprinted with “WPI” over “3363” in black ink, supplied in bottles of 30, 90 and 1000.420 mg: white to off-white round tablets imprinted with “WPI” over “3364” in black ink, supplied in bottles of 30, 90 and 1000.StoreAvoid excessive humidity and temperatures above 30°C (86°F).Dispense in tight, light resistant container as defined in USP.Rx Only.Watson Laboratories Inc.Corona, CA 92880 USARev. October 2005Diltiazem Hydrochloride Extended Release Tablets are supplied as:120 mg: white to off-white round tablets imprinted with “WPI” over “3360” in black ink, supplied in bottles of 30, 90 and 1000.180 mg: white to off-white round tablets imprinted with “WPI” over “3361” in black ink, supplied in bottles of 30, 90 and 1000.240 mg: white to off-white round tablets imprinted with “WPI” over “3362” in black ink, supplied in bottles of 30, 90 and 1000.300 mg: white to off-white round tablets imprinted with “WPI” over “3368” in black ink, supplied in bottles of 30, 90 and 1000.360 mg: white to off-white round tablets imprinted with “WPI” over “3363” in black ink, supplied in bottles of 30, 90 and 1000.420 mg: white to off-white round tablets imprinted with “WPI” over “3364” in black ink, supplied in bottles of 30, 90 and 1000.StoreAvoid excessive humidity and temperatures above 30°C (86°F).Dispense in tight, light resistant container as defined in USP.Rx Only.Watson Laboratories Inc.Corona, CA 92880 USARev. October 2005Diltiazem Hydrochloride Extended Release Tablets are supplied as:120 mg: white to off-white round tablets imprinted with “WPI” over “3360” in black ink, supplied in bottles of 30, 90 and 1000.180 mg: white to off-white round tablets imprinted with “WPI” over “3361” in black ink, supplied in bottles of 30, 90 and 1000.240 mg: white to off-white round tablets imprinted with “WPI” over “3362” in black ink, supplied in bottles of 30, 90 and 1000.300 mg: white to off-white round tablets imprinted with “WPI” over “3368” in black ink, supplied in bottles of 30, 90 and 1000.360 mg: white to off-white round tablets imprinted with “WPI” over “3363” in black ink, supplied in bottles of 30, 90 and 1000.420 mg: white to off-white round tablets imprinted with “WPI” over “3364” in black ink, supplied in bottles of 30, 90 and 1000.StoreAvoid excessive humidity and temperatures above 30°C (86°F).Dispense in tight, light resistant container as defined in USP.Rx Only.Watson Laboratories Inc.Corona, CA 92880 USARev. October 2005Diltiazem Hydrochloride Extended Release Tablets are supplied as:120 mg: white to off-white round tablets imprinted with “WPI” over “3360” in black ink, supplied in bottles of 30, 90 and 1000.180 mg: white to off-white round tablets imprinted with “WPI” over “3361” in black ink, supplied in bottles of 30, 90 and 1000.240 mg: white to off-white round tablets imprinted with “WPI” over “3362” in black ink, supplied in bottles of 30, 90 and 1000.300 mg: white to off-white round tablets imprinted with “WPI” over “3368” in black ink, supplied in bottles of 30, 90 and 1000.360 mg: white to off-white round tablets imprinted with “WPI” over “3363” in black ink, supplied in bottles of 30, 90 and 1000.420 mg: white to off-white round tablets imprinted with “WPI” over “3364” in black ink, supplied in bottles of 30, 90 and 1000.StoreAvoid excessive humidity and temperatures above 30°C (86°F).Dispense in tight, light resistant container as defined in USP.Rx Only.Watson Laboratories Inc.Corona, CA 92880 USARev. October 2005Diltiazem Hydrochloride Extended Release Tablets are supplied as:120 mg: white to off-white round tablets imprinted with “WPI” over “3360” in black ink, supplied in bottles of 30, 90 and 1000.180 mg: white to off-white round tablets imprinted with “WPI” over “3361” in black ink, supplied in bottles of 30, 90 and 1000.240 mg: white to off-white round tablets imprinted with “WPI” over “3362” in black ink, supplied in bottles of 30, 90 and 1000.300 mg: white to off-white round tablets imprinted with “WPI” over “3368” in black ink, supplied in bottles of 30, 90 and 1000.360 mg: white to off-white round tablets imprinted with “WPI” over “3363” in black ink, supplied in bottles of 30, 90 and 1000.420 mg: white to off-white round tablets imprinted with “WPI” over “3364” in black ink, supplied in bottles of 30, 90 and 1000.StoreAvoid excessive humidity and temperatures above 30°C (86°F).Dispense in tight, light resistant container as defined in USP.Rx Only.Watson Laboratories Inc.Corona, CA 92880 USARev. October 2005Diltiazem Hydrochloride Extended Release Tablets are supplied as:120 mg: white to off-white round tablets imprinted with “WPI” over “3360” in black ink, supplied in bottles of 30, 90 and 1000.180 mg: white to off-white round tablets imprinted with “WPI” over “3361” in black ink, supplied in bottles of 30, 90 and 1000.240 mg: white to off-white round tablets imprinted with “WPI” over “3362” in black ink, supplied in bottles of 30, 90 and 1000.300 mg: white to off-white round tablets imprinted with “WPI” over “3368” in black ink, supplied in bottles of 30, 90 and 1000.360 mg: white to off-white round tablets imprinted with “WPI” over “3363” in black ink, supplied in bottles of 30, 90 and 1000.420 mg: white to off-white round tablets imprinted with “WPI” over “3364” in black ink, supplied in bottles of 30, 90 and 1000.StoreAvoid excessive humidity and temperatures above 30°C (86°F).Dispense in tight, light resistant container as defined in USP.Rx Only.Watson Laboratories Inc.Corona, CA 92880 USARev. October 2005Diltiazem Hydrochloride Extended Release Tablets are supplied as:120 mg: white to off-white round tablets imprinted with “WPI” over “3360” in black ink, supplied in bottles of 30, 90 and 1000.180 mg: white to off-white round tablets imprinted with “WPI” over “3361” in black ink, supplied in bottles of 30, 90 and 1000.240 mg: white to off-white round tablets imprinted with “WPI” over “3362” in black ink, supplied in bottles of 30, 90 and 1000.300 mg: white to off-white round tablets imprinted with “WPI” over “3368” in black ink, supplied in bottles of 30, 90 and 1000.360 mg: white to off-white round tablets imprinted with “WPI” over “3363” in black ink, supplied in bottles of 30, 90 and 1000.420 mg: white to off-white round tablets imprinted with “WPI” over “3364” in black ink, supplied in bottles of 30, 90 and 1000.StoreAvoid excessive humidity and temperatures above 30°C (86°F).Dispense in tight, light resistant container as defined in USP.Rx Only.Watson Laboratories Inc.Corona, CA 92880 USARev. October 2005


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

The renal clearance of sodium iothalamate in man closely approximates that of inulin. The compound is cleared by glomerular filtration without tubular secretion or reabsorption. Following infusion administration of I-125 iothalamate, the effective half-life is about 0.07 days.

Non-Clinical Toxicology
GLOFIL-125 should not be administered via a central venous line.

None known.

Due to the potential for additive effects, caution and careful titration are warranted in patients receiving diltiazem concomitantly with other agents known to affect cardiac contractility and/or conduction (). Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with diltiazem ().

As with all drugs, care should be exercised when treating patients with multiple medications. Diltiazem is both a substrate and an inhibitor of the cytochrome P-450 3A4 enzyme system. Other drugs that are specific substrates, inhibitors, or inducers of this enzyme system may have a significant impact on the efficacy and side effect profile of diltiazem. Patients taking other drugs that are substrates of CYP450, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to maintain optimum therapeutic blood levels.

As in the use of any radioactive material, care should be taken to minimize radiation exposure to the patient, consistent with proper patient management, and to insure minimum radiation exposure to occupational workers.

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides.

Rapid or bolus-like injections should be avoided.

None reported.

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).